HIV-Associated Lymphomas: Progress and New Challenges

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Mar 10

PMID 35268547

Authors

Georgios N Pongas

Juan C Ramos

Affiliations

Soon will be listed here.

Abstract

The association of human immunodeficiency virus (HIV) and aggressive lymphomas was first reported in 1982. Before the development of effective HIV antiviral therapy, the incidence and the mortality of these lymphomas was high, with patients frequently succumbing to the disease. More lately, the combination of cART with chemoimmunotherapy significantly improved the survival outcome of the HIV-lymphomas. In this review, we discuss on describing the incidence of HIV-associated lymphomas, their clinical features, and the latest advances in the management of the various lymphoma subtypes.

Citing Articles

Synthesis and antitumor activity of dolutegravir derivatives bearing 1,2,3-triazole moieties.

Hou X, Mao L, Guo Y, Wang L, Peng L, Wang H BMC Chem. 2024; 18(1):97.

PMID: 38715128 PMC: 11077815. DOI: 10.1186/s13065-024-01205-3.

How can we establish animal models of HIV-associated lymphoma?.

Xiao Q, Zhai L, Zhang X, Liu Y, Li J, Xie X Animal Model Exp Med. 2024; 7(4):484-496.

PMID: 38567763 PMC: 11369037. DOI: 10.1002/ame2.12409.

Carcinogenic mechanisms of virus-associated lymphoma.

Zhang Y, Guo W, Zhan Z, Bai O Front Immunol. 2024; 15:1361009.

PMID: 38482011 PMC: 10932979. DOI: 10.3389/fimmu.2024.1361009.

The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends.

Chu Y, Liu Y, Fang X, Jiang Y, Ding M, Ge X Front Oncol. 2023; 13:1059914.

PMID: 37333805 PMC: 10272809. DOI: 10.3389/fonc.2023.1059914.

Clinical value of F-FDG PET/CT in the management of HIV-associated lymphoma.

Liu Q, Yang T, Chen X, Liu Y Front Oncol. 2023; 13:1117064.

PMID: 36776334 PMC: 9909962. DOI: 10.3389/fonc.2023.1117064.

References

Scholler J, Brady T, Binder-Scholl G, Hwang W, Plesa G, Hege K . Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012; 4(132):132ra53. PMC: 4368443. DOI: 10.1126/scitranslmed.3003761. View

Murata T, Sugimoto A, Inagaki T, Yanagi Y, Watanabe T, Sato Y . Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation. Viruses. 2021; 13(12). PMC: 8706188. DOI: 10.3390/v13122344. View

Noy A . Optimizing treatment of HIV-associated lymphoma. Blood. 2019; 134(17):1385-1394. PMC: 7493463. DOI: 10.1182/blood-2018-01-791400. View

Moulignier A, Lamirel C, Picard H, Lebrette M, Amiel C, Hamidi M . Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy. Neurology. 2017; 89(8):796-804. DOI: 10.1212/WNL.0000000000004265. View

Lurain K, Uldrick T, Ramaswami R, Polizzotto M, Goncalves P, Widell A . Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood. 2020; 136(19):2229-2232. PMC: 7645985. DOI: 10.1182/blood.2020006048. View

Patel P, Hanson D, Sullivan P, Novak R, Moorman A, Tong T . Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008; 148(10):728-36. DOI: 10.7326/0003-4819-148-10-200805200-00005. View

Castillo J, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S . Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2018; 184(4):679-682. DOI: 10.1111/bjh.15156. View

Castillo J, Bibas M, Miranda R . The biology and treatment of plasmablastic lymphoma. Blood. 2015; 125(15):2323-30. DOI: 10.1182/blood-2014-10-567479. View

Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W . Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Sci Transl Med. 2019; 11(504). PMC: 7136029. DOI: 10.1126/scitranslmed.aav5685. View

10.

Shiels M, Pfeiffer R, Gail M, Hall H, Li J, Chaturvedi A . Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011; 103(9):753-62. PMC: 3086877. DOI: 10.1093/jnci/djr076. View

11.

Kaplan L, Straus D, Testa M, Von Roenn J, Dezube B, Cooley T . Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997; 336(23):1641-8. DOI: 10.1056/NEJM199706053362304. View

12.

MacMahon E, Glass J, Hayward S, Mann R, Becker P, CHARACHE P . Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991; 338(8773):969-73. DOI: 10.1016/0140-6736(91)91837-k. View

13.

Ghosh S, Perrine S, Williams R, Faller D . Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood. 2011; 119(4):1008-17. PMC: 3271713. DOI: 10.1182/blood-2011-06-362434. View

14.

. Revision of the case definition of acquired immunodeficiency syndrome for national reporting--United States. MMWR Morb Mortal Wkly Rep. 1985; 34(25):373-5. View

15.

Sparano J, Lee J, Kaplan L, Levine A, Ramos J, Ambinder R . Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2009; 115(15):3008-16. PMC: 2858478. DOI: 10.1182/blood-2009-08-231613. View

16.

Grulich A, van Leeuwen M, Falster M, Vajdic C . Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370(9581):59-67. DOI: 10.1016/S0140-6736(07)61050-2. View

17.

Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon V . Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood. 2006; 108(4):1174-82. PMC: 1895868. DOI: 10.1182/blood-2005-09-008086. View

18.

Baumgartner J, Rachlin J, Beckstead J, Meeker T, Levy R, Wara W . Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg. 1990; 73(2):206-11. DOI: 10.3171/jns.1990.73.2.0206. View

19.

Shiozawa K, Nakanishi T, Tan M, Fang H, Wang W, Edelman M . Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res. 2009; 15(5):1698-707. DOI: 10.1158/1078-0432.CCR-08-1587. View

20.

Barta S, Samuel M, Xue X, Wang D, Lee J, Mounier N . Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol. 2015; 26(5):958-966. PMC: 4405278. DOI: 10.1093/annonc/mdv036. View